Laparoscopic sleeve gastrectomy increased medication reduction or discontinuation for obesity-related comorbidities to 100% compared to 10% with conservative management (ARR 0.91).
Cohort (n=60)
No
Does laparoscopic sleeve gastrectomy improve the reduction or discontinuation of pharmacologic treatment for obesity-related comorbidities compared to conservative management in patients aged ≥ 65 years with severe obesity?
In patients aged 65 and older with severe obesity, laparoscopic sleeve gastrectomy significantly improved weight loss and the reduction or discontinuation of medications for obesity-related comorbidities compared to conservative management.
Effect estimate: ARR 0.91 (95% CI 0.79-1.00)
Absolute Event Rate: 100% vs 10%
p-value: p=<0.001
Obesity in adults over 65 years is increasingly prevalent and linked to comorbidities like type 2 diabetes (T2D), hypertension (HTN), osteoarthritis (OA), and obstructive sleep apnea (OSA), where conservative treatments often fail. Laparoscopic sleeve gastrectomy (LSG) effectively treats severe obesity, but prospective comparisons with non-surgical management in this age group are limited. This prospective, non-randomized, patient-preference cohort study enrolled 60 patients aged ≥ 65 years with BMI ≥ 40 kg/m² and ≥ 1 comorbidity (T2D, HTN, OA, or OSA). Group A (n = 30) underwent LSG; Group B (n = 30) received conservative management (diet counseling, pharmacotherapy), with 12‑month follow‑up. The prespecified primary endpoint was reduction or discontinuation of pharmacologic treatment for at least one baseline weight‑related comorbidity; secondary endpoints included weight loss, comorbidity‑specific outcomes, and postoperative complications.. Baseline characteristics were balanced between groups. At 12 months, medication reduction or discontinuation for at least one obesity-related comorbidity occurred in 100% of patients after LSG versus 10% with conservative management (adjusted absolute risk difference 0.91, 95% CI 0.79–1.00, p < 0.001). LSG achieved 30.7% total body weight loss and 63.1% excess weight loss compared with 2.9% and 6.2%, respectively, in the conservative group (both p < 0.001). Multivariable-adjusted analyses showed that LSG was associated with greater reductions in weight (− 37.9 kg, 95% CI − 40.5 to − 35.2, p < 0.001), BMI (− 13.6 kg/m², 95% CI − 14.6 to − 12.6, p < 0.001), HbA1c (− 1.36%, 95% CI − 1.74 to − 0.96, p < 0.001), systolic blood pressure (− 4.5 mmHg, 95% CI − 8.0 to − 1.0, p = 0.02), and AHI (− 14.8 events/hour, 95% CI − 17.1 to − 12.4, p < 0.001), and with increased right knee joint space width (+ 0.33 mm, 95% CI 0.17–0.49, p < 0.001) at 12 months. In carefully selected patients over 65 years, LSG was associated with greater medication reduction, comorbidity improvement, and weight loss compared with conservative management, with an acceptable safety profile and no mortality. LSG may be actively considered for elderly patients with severe obesity and multiple weight-related comorbidities.
Gheda et al. (Thu,) conducted a cohort in Severe obesity with weight-related comorbidities (n=60). Laparoscopic sleeve gastrectomy vs. Conservative management was evaluated on Reduction or discontinuation of pharmacologic treatment for at least one baseline obesity-related comorbidity (ARR 0.91, 95% CI 0.79-1.00, p=<0.001). Laparoscopic sleeve gastrectomy increased medication reduction or discontinuation for obesity-related comorbidities to 100% compared to 10% with conservative management (ARR 0.91).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: